Experimental drug reverses fatty liver disease by repairing the gut
7 hours ago
- #gut-liver axis
- #experimental drug
- #MASH
- Experimental drug DT-109 reversed severe fatty liver disease (MASH) in animal studies by repairing the gut barrier and reducing harmful microbial products.
- DT-109 reduces Clostridium perfringens levels and ammonia in the gut, protecting liver health and lowering inflammation.
- Potential uses for DT-109 extend beyond MASH to cardiovascular disease and digestive disorders like inflammatory bowel disease.
- The drug's mechanism involves modulating gut microbiota and preventing systemic translocation of toxins through the gut-liver axis.
- Future research will focus on clinical trials to evaluate safety and effectiveness in humans for treating MASH.